Keywords: AstrZeneca, Seroquel, Monotherapy, Major depressive disorder, FDA

Safety and clinical benefits of AstraZeneca’s Seroquel XR need to be demonstrated for its approval as an MDD monotherapy, says DR

Article | 28 January 2010

• Print This

The recent decision by the US Food and Drug Administration to grant approval of Anglo-Swedish drug major AstraZeneca's Seroquel XR (quetiapine fumarate) for adjunctive treatment of major depressive disorder will not change Decision Resources' market projection for the indication. As previously forecast by the research and advisory firm, Seroquel and Seroquel XR will garner nearly one quarter of antipsychotics sales as adjunctive treatments for major depressive disorder in 2013 in the world's major pharmaceutical markets.

T Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.